文献速递瓣膜病与结构性心脏病

PARTNER试验中经导管与外科主动脉瓣的纵向血流动力学

Longitudinal Hemodynamics of Transcatheter and Surgical Aortic Valves in the PARTNER Trial.
PubMed 文献 · JAMA Cardiol · 2017-01-01

该研究基于PARTNER 1试验及继续访问研究,由核心实验室分析超声心动图数据,评估经导管主动脉瓣(TAVR)与外科主动脉瓣置换(SAVR)的中期血流动力学表现。共纳入2795例患者,平均年龄84.5岁,女性占47.0%。结果显示TAVR后早期血流动力学有小幅改善,随后相对稳定,SAVR无显著变化;再干预罕见,仅5例TAVR因瓣膜结构 deterioration 需再干预。

要点

  • TAVR后早期平均跨瓣压差下降2.9 mmHg,有效瓣口面积增加0.09 cm²,随后3.1年内相对稳定。
  • TAVR后中重度瓣周漏见于3.7%患者,且随时间增加;SAVR无显著血流动力学变化。
  • TAVR再干预率0.8%,SAVR 0.3%,仅5例TAVR因瓣膜结构 deterioration 需再干预。

核心结论

  • 经导管心脏瓣膜和SAVR均显示出良好的耐久性,个体患者中提示瓣膜血栓或结构 deterioration 的异常发现罕见。

研究设计与样本

  • 分析PARTNER 1试验(1A:TAVR n=321,SAVR n=313;1B:TAVR n=165)及继续访问研究(TAVR n=1996)中所有成功TAVR或SAVR患者的核心实验室超声心动图数据,共2795例,平均年龄84.5岁,女性47.0%。

主要发现

  • TAVR后最初数月平均跨瓣压差下降2.9 mmHg,多普勒速度指数增加0.028,有效瓣口面积增加0.09 cm²,中位随访3.1年(最长5年)内相对稳定。
  • TAVR后中重度跨瓣反流见于89例(3.7%),且随时间增加;SAVR患者无显著变化。
  • TAVR再干预20例(0.8%),SAVR再干预1例(0.3%),仅5例TAVR再干预由瓣膜结构 deterioration 导致。
  • TAVR后死亡或再干预与较低射血分数、每搏输出量指数及较低平均跨瓣压差相关(至3年),与多普勒速度指数或瓣口面积无关。

临床怎么用

  • TAVR术后中期血流动力学总体稳定,但需关注中重度跨瓣反流随时间增加的趋势。
  • 超声心动图显示严重异常血流动力学不常见,且未与超额死亡或再干预相关,个体异常发现需进一步评估。

局限性

  • 5年超声心动图数据仅覆盖部分患者(TAVR 424例,SAVR 49例)。
  • 异常发现(提示瓣膜血栓或结构 deterioration)罕见,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Use of transcatheter aortic valve replacement (TAVR) for severe aortic stenosis is growing rapidly. However, to our knowledge, the durability of these prostheses is incompletely defined. OBJECTIVE: To determine the midterm hemodynamic performance of balloon-expandable transcatheter heart valves. DESIGN, SETTING, AND PARTICIPANTS: In this study, we analyzed core laboratory-generated data from echocardiograms of all patients enrolled in the Placement of Aortic Transcatheter Valves (PARTNER) 1 Trial with successful TAVR or surgical AVR (SAVR) obtained preimplantation and at 7 days, 1 and 6 months, and 1, 2, 3, 4, and 5 years postimplantation. Patients from continued access observational studies were included for comparison. INTERVENTIONS: Successful implantation after randomization to TAVR vs SAVR (PARTNER 1A; TAVR, n = 321; SAVR, n = 313), TAVR vs medical treatment (PARTNER 1B; TAVR, n = 165), and continued access (TAVR, n = 1996). Five-year echocardiogram data were available for 424 patients after TAVR and 49 after SAVR. MAIN OUTCOMES AND MEASURES: Death or reintervention for aortic valve structural indications, measured using aortic valve mean gradient, effective orifice area, Doppler velocity index, and evidence of hemodynamic deterioration by reintervention, adverse hemodynamics, or transvalvular regurgitation. RESULTS: Of 2795 included patients, the mean (SD) age was 84.5 (7.1) years, and 1313 (47.0%) were female. Population hemodynamic trends derived from nonlinear mixed-effects models showed small early favorable changes in the first few months post-TAVR, with a decrease of -2.9 mm Hg in aortic valve mean gradient, an increase of 0.028 in Doppler velocity index, and an increase of 0.09 cm2 in effective orifice area. There was relative stability at a median follow-up of 3.1 (maximum, 5) years. Moderate/severe transvalvular regurgitation was noted in 89 patients (3.7%) after TAVR and increased over time. Patients with SAVR showed no significant changes. In TAVR, death/reintervention was associated with lower ejection fraction, stroke volume index, and aortic valve mean gradient up to 3 years, with no association with Doppler velocity index or valve area. Reintervention occurred in 20 patients (0.8%) after TAVR and in 1 (0.3%) after SAVR and became less frequent over time. Reintervention was caused by structural deterioration of transcatheter heart valves in only 5 patients. Severely abnormal hemodynamics on echocardiograms were also infrequent and not associated with excess death or reintervention for either TAVR or SAVR. CONCLUSIONS AND RELEVANCE: This large, core laboratory-based study of transcatheter heart valves revealed excellent durability of the transcatheter heart valves and SAVR. Abnormal findings in individual patients, suggestive of valve thrombosis or structural deterioration, were rare in this protocol-driven database and require further investigation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00530894.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Douglas PS, Leon MB, Mack MJ, et al. Longitudinal Hemodynamics of Transcatheter and Surgical Aortic Valves in the PARTNER Trial. JAMA Cardiol. 2017. PMID: 28973520. doi:10.1001/jamacardio.2017.3306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。